Medigen Biotechnology (ROCO:3176) Institutional Ownership: 3.39% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
55 GF Score
Price NT$34.15
GF Value NT$37.02
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Medigen Biotechnology Institutional Ownership?

Medigen Biotechnology ROCO:3176 +1.19% 55 Institutional Ownership is 3.39% as of Aug. 18, 2026. GuruFocus rates ROCO:3176 with a GF Score™ of 55/100 and a GF Value™ of NT$37.02 (Fairly Valued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medigen Biotechnology's institutional ownership is 3.39%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medigen Biotechnology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medigen Biotechnology's Float Percentage Of Total Shares Outstanding is 0.00%.

Medigen Biotechnology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Institutional Ownership Chart

Medigen Biotechnology Historical Data

The historical data trend for Medigen Biotechnology can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 3.32 3.34 3.34 3.34 3.34 3.35 3.35 3.35 3.39 3.39
ROCO:3176
55GF Score
Medigen Biotechnology Corp ROCO:3176
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.39% mean?
Medigen Biotechnology (ROCO:3176) has a Institutional Ownership of 3.39% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Institutional Ownership too high?
Medigen Biotechnology's current Institutional Ownership is 3.39%. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Institutional Ownership compare to VRTX and REGN?
Medigen Biotechnology's Institutional Ownership of 3.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Institutional Ownership is 3.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.02, compared to a current price of NT$34.15 — trading 7.8% below its estimated fair value. The current Institutional Ownership is 3.39%. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Institutional Ownership is 3.39% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$34.15 is trading 7.8% below its estimated GF Value™ of NT$37.02. GuruFocus considers Medigen Biotechnology to be Fairly Valued.

Key valuation signals for ROCO:3176:

  • Institutional Ownership: 3.39%
  • GF Value™: NT$37.02 vs. price of NT$34.15 (7.8% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score

Get the complete analysis for ROCO:3176

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.15
Price
NT$37.02
GF Value